Valbiotis SA (FRA:8JD)

Market Cap	24.37M +14.5%
Revenue (ttm)	474.00K -10.1%
Net Income	-11.12M
EPS	-0.70
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	157
Open	0.984
Previous Close	0.982
Day's Range	0.984 - 1.066
52-Week Range	0.527 - 1.300
Beta	n/a
RSI	52.35
Earnings Date	Mar 3, 2026

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laborato...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 44
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8JD

Financial Performance

In 2024, Valbiotis's revenue was 176,000, a decrease of -96.28% compared to the previous year's 4.73 million. Losses were -10.03 million, 36.1% more than in 2023.